Literature DB >> 15876876

The Plk1 Polo box domain mediates a cell cycle and DNA damage regulated interaction with Chk2.

Lyuben M Tsvetkov1, Rumiana T Tsekova, Xingzhi Xu, David F Stern.   

Abstract

Polo-like kinase 1 (Plk1) regulates multiple processes during mitosis. Chk2 is a tumor suppressor that participates in DNA damage checkpoint signaling cascades. Plk1 phosphorylates, colocalizes with, and interacts with Chk2, suggesting interconnection of DNA damage checkpoints and mitotic regulation. However, the function of their association is unknown. Here, we show that the interaction between Chk2 and Plk1 is cell cycle-regulated, with a peak in mitosis. DNA damage in G2 and M phases but not in S phase induces dissociation of Plk1 and Chk2. In vitro, the Plk1 PBD binds phosphorylated Chk2, and mediates an interaction independent of other eukaryotic proteins. Additionally, a phosphopeptide encompassing phosphoT68 of Chk2 binds Plk1 in a PBD-dependent manner, and stimulates Plk1 activity. These results identify potential mechanisms for interaction and inter-regulation of these two protein kinases.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15876876

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  9 in total

1.  Centrosomal Chk2 in DNA damage responses and cell cycle progression.

Authors:  Amnon Golan; Elah Pick; Lyuben Tsvetkov; Yasmine Nadler; Harriet Kluger; David F Stern
Journal:  Cell Cycle       Date:  2010-07-01       Impact factor: 4.534

Review 2.  Repair of topoisomerase I-mediated DNA damage.

Authors:  Yves Pommier; Juana M Barcelo; V Ashutosh Rao; Olivier Sordet; Andrew G Jobson; Laurent Thibaut; Ze-Hong Miao; Jennifer A Seiler; Hongliang Zhang; Christophe Marchand; Keli Agama; John L Nitiss; Christophe Redon
Journal:  Prog Nucleic Acid Res Mol Biol       Date:  2006

Review 3.  Recent advances in intravesical drug/gene delivery.

Authors:  Pradeep Tyagi; Pao-Chu Wu; Michael Chancellor; Naoki Yoshimura; Leaf Huang
Journal:  Mol Pharm       Date:  2006 Jul-Aug       Impact factor: 4.939

Review 4.  Mitotic crisis: the unmasking of a novel role for RPA.

Authors:  Rachel William Anantha; James A Borowiec
Journal:  Cell Cycle       Date:  2009-02-21       Impact factor: 4.534

5.  CDC5 inhibits the hyperphosphorylation of the checkpoint kinase Rad53, leading to checkpoint adaptation.

Authors:  Genevieve M Vidanes; Frédéric D Sweeney; Sarah Galicia; Stephanie Cheung; John P Doyle; Daniel Durocher; David P Toczyski
Journal:  PLoS Biol       Date:  2010-01-26       Impact factor: 8.029

Review 6.  The role of polo-like kinase 1 in carcinogenesis: cause or consequence?

Authors:  Brian D Cholewa; Xiaoqi Liu; Nihal Ahmad
Journal:  Cancer Res       Date:  2013-11-21       Impact factor: 12.701

7.  Elevated levels of the polo kinase Cdc5 override the Mec1/ATR checkpoint in budding yeast by acting at different steps of the signaling pathway.

Authors:  Roberto Antonio Donnianni; Matteo Ferrari; Federico Lazzaro; Michela Clerici; Benjamin Tamilselvan Nachimuthu; Paolo Plevani; Marco Muzi-Falconi; Achille Pellicioli
Journal:  PLoS Genet       Date:  2010-01-22       Impact factor: 5.917

8.  Gene expression patterns in heterozygous Plk4 murine embryonic fibroblasts.

Authors:  Alan Morettin; Alejandra Ward; Jordan Nantais; John W Hudson
Journal:  BMC Genomics       Date:  2009-07-16       Impact factor: 3.969

9.  An inverse switch in DNA base excision and strand break repair contributes to melphalan resistance in multiple myeloma cells.

Authors:  Mirta M L Sousa; Kamila Anna Zub; Per Arne Aas; Audun Hanssen-Bauer; Aida Demirovic; Antonio Sarno; Erming Tian; Nina B Liabakk; Geir Slupphaug
Journal:  PLoS One       Date:  2013-02-06       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.